

Assessment of a multistrain probiotic in inflammatory bowel disease (IBD)

Submission date 28/06/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 05/08/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 11/04/2017	Condition category Digestive System	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Guy Sisson

Contact details
Department of Gastroenterology
King's College Hospital
Denmark Hill
London
United Kingdom
SE5 9RS
+44 (0)20 3299 8773
guy.sisson@kch.nhs.uk

Additional identifiers

Protocol serial number
080609/02; KCH1636

Study information

Scientific Title
Assessment of a multistrain probiotic (symprove) as a dietary supplement in patients with inflammatory bowel disease who are in 'clinical' remission

Study objectives

Regular use of this multistrain probiotic may have anti-inflammatory properties and help improve the residual symptoms of inflammatory bowel disease (IBD) experienced by patients in 'clinical remission'.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Outer South East London Research Ethics Committee, 01/10/2009, ref: 09/H0805/37

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Inflammatory bowel disease (ulcerative colitis and Crohn's disease)

Interventions

160 patients with mild/moderate IBD will be randomly assigned (1:1 UC and 1:1 Crohn's disease) to receive 1 ml/kg/day (max 100 ml) of probiotic or placebo for 4 weeks.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Symprove

Primary outcome(s)

Improvement in Inflammatory Bowel Disease Questionnaire (IBDQ) score at week 4

Key secondary outcome(s)

Reduction in faecal calprotectin at week 4

Completion date

01/07/2011

Eligibility**Key inclusion criteria**

1. Patients aged 18 - 65 years, either sex
2. Minimum 6 months history of inflammatory bowel disease

3. Confirmed both endoscopically and histologically
4. Three months of 'stable clinical remission' - including no change in treatment during the preceding 3 months

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

65 years

Sex

All

Key exclusion criteria

1. Aged less than 16 years and greater than 65 years
2. Severe disease or current disease flare
3. Current use of biological or immunosuppressive treatments (including infliximab, adalimumab, methotrexate, azathioprine, 6-mercaptopurine, cyclosporin). Patients who are taking azathioprine or 6-mercaptopurine who have been stable on treatment for a minimum of 12 weeks without major side effects or adverse events will not be excluded.
4. Previous complicated bowel resections or multiple bowel resections
5. Pregnancy or actively seeking pregnancy
6. History of intolerance or allergy to probiotics
7. Significant comorbid conditions (to be judged by the research doctor at assessment)
8. Significant psychiatric comorbidity (to be judged by the research doctor at assessment)
9. Current drug or alcohol dependence syndrome

Date of first enrolment

01/07/2010

Date of final enrolment

01/07/2011

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre
King's College Hospital
London
United Kingdom
SE5 9RS

Sponsor information

Organisation
Kings College Hospital NHS Foundation Trust (UK)

ROR
<https://ror.org/01n0k5m85>

Funder(s)

Funder type
Other

Funder Name
Investigator initiated and funded (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration